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studied only with great difficulty or at great expense. An
example is the study of vaccination in patients with end-
stage renal disease by Gilbertson et al [7]. By its nature,
such a study could never be attempted in a randomized
trial.
We appreciate this opportunity to discuss our work.
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Challenges from bias when
estimating change of renal
allograft function
To the Editor: In the February issue of Kidney In-
ternational, Gill et al [1] aimed to examine the asso-
ciations between immunosuppressive regimens and the
change of renal allograft function. Their analytical strat-
egy, in concert with missing data and measurement er-
ror that is systematically different between centers that
differentially use types of calcineurin inhibitors, rein-
forces the substantive limitations of using databases to
address particular hypotheses. First, repeated measures
of renal function entail an analytical strategy that con-
siders within subject correlation [2, 3]. Second, change
of renal function may not be measured uniformly during
post-transplant between regimens as a consequence of
the pattern of missingness of serum creatinines across
eras of transplantation, which are associated with the
prevalence of regimens. The time post-transplant when
change is measured is important as the slope of creati-
nine evolves. Third, there is significant calibration bias for
measurement of serum creatinines that exists across med-
ical centers, which is associated with the type of regimen
[4]. The summation of the biases—the lack of consider-
ation for intrasubject correlation, the nonuniform mea-
surement of change of renal function across regimens,
and the measurement error of serum creatinines across
centers, overshadows the meaningfulness of the conclu-
sions, and contributes to the unique observations asso-
ciated with tacrolimus—lowest mean glomerular filtra-
tion rate (GFR) at one year after transplant (see Table 1)
and the implausible positive change of renal function (see
Table 3). Understanding the impact of immunosuppres-
sive strategies on the change of renal function overtime is
important; however, this is best examined in prospective
studies, and caution is advised when applying this study’s
observations to the management of transplant recipients.
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Reply from the Authors
We thank Dr. Mange for his letter drawing attention
to the potential of bias in observational studies such as
ours. He has raised three issues:
First, we agree that longitudinal studies that analyze se-
rial measurements from the same patient must consider
the impact of autocorrelation caused by repeated mea-
sures. We used a two-step regression procedure, which
fully accounts for any effects of repeated measures. Our
primary outcome, the annualized change in GFR, was cal-
culated by fitting a regression line through each patient’s
serial GFR estimates. This accepted technique reduces
the rate of change in GFR to a single outcome measure
per patient—a slope. These slopes were then examined
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for adjusted association with immunosuppressants in sub-
sequent regression models. Therefore, Dr. Mange can be
reassured that our results are not influenced by the mul-
tiple estimates of GFR per patient.
Second, Dr. Mange suggests that creatinine measure-
ments may be differentially missing between patients
who received different immunosuppressants. Nonran-
dom missing data could introduce bias if the annualized
change in GFR differed in patients with and without
missing creatinine measurements. All study patients had
three creatinine measurements recorded in the first two
post-transplant years, and over 80% of all creatinine mea-
surements were available during follow-up. There was no
association between missing creatinine values and trans-
plant year or type of immunosuppression; therefore, bias
caused by nonrandom missing values is very unlikely.
Third, Dr. Mange suggests bias caused by differences in
the methods used to measure creatinine between trans-
plant centers. In order for this to affect our results, the
creatinine assays in centers using tacrolimus (or my-
cophenolate) would have to systematically differ from
centers using cyclosporine (or azathioprine)—which
seems very improbable. Nonetheless, because most
patients would have creatinine measurements in the same
center, the annualized change in GFR in individual pa-
tients would not be affected by differences in assays be-
tween centers.
As discussed in our manuscript, we agree that readers
must consider a variety of limitations inherent to analy-
ses of large databases. However, we do not believe that
particular issues raised in this letter are relevant to our
analysis.
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Development of malignancy
after treatment of idiopathic
membranous nephropathy
To the Editor: With great interest, we have read
the paper in a recent issue of Kidney International by
Keiichi Yoshimoto et al [1] that pathologic findings
of initial biopsies reflect the outcomes of membranous
nephropathy (MN). In this study, seven patients (7/105 ×
100% = 6.66%) eventually died of malignancies (gastric
cancer 3, pancreatic cancer 1, lung cancer 1, laryngeal
cancer 1, leukemia 1). Although they were diagnosed
initially as idiopathic membranous nephropathy, we won-
dered whether the malignancy was the underlying cause
of MN or the complication of long-term immunosup-
pressive therapy (e.g., cyclophosphamide). MN had been
reported to be associated with neoplasms, and some
patients with malignancies had been documented pre-
senting with nephrotic-range proteinuria. In David’s
study [2], nine of 87 (9/87 × 100% = 10.3%) “idiopathic”
MN patients were associated with malignancy. Hence, a
search for malignancy is warranted in all adult patients
presenting with MN. Pathologically, deposits at sites other
than the subepithelial aspect of the glomerular basement
membrane (GBM) favor the presence of secondary forms
of MN. We would like to know if any deposits were
identified at mesangial, subendothelial, tubular basement
membrane, interstitial, or vessel area in these seven ma-
lignant patients. We would also like to know whether
there was any difference in the pathologic findings (ac-
cording to Yoshimoto’s classification) between the seven
malignant patients and those without malignancies. On
the other hand, the possible carcinogenic effect of long-
term immunosuppressive therapy should be also con-
sidered because the carcinogenic potency of alkylating
agents had been reported in the literature [3].
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Reply from the authors
We would like to thank you for the interest to our article
[1]. We agree with the comments that a search for malig-
nancy is warranted in all adult patients with membranous
nephropathy; therefore, we routinely examined them by
chest x-ray, upper gastrointestinal endoscopic study, ab-
dominal ultrasonography, or computed tomography, and
stool occult blood (if positive, lower gastrointestinal en-
doscopic study). Seven patients died with malignancy in
our study, but malignancy was not detected in all of them
at first as described [1].
Three of seven patients were treated with corticos-
teroid and cyclophosphamide, one patient with gamma
globulin and cyclophosphamide, two patients with corti-
